Abivax Target of Unusually Large Options Trading (NASDAQ:ABVX)

Abivax SA Sponsored ADR (NASDAQ:ABVX) was the recipient of some unusual options trading on Tuesday. Stock traders purchased 6,598 call options on the stock. This is an increase of 89% compared to the typical daily volume of 3,492 call options.

Analysts Set New Price Targets

Several analysts have weighed in on ABVX shares. Morgan Stanley boosted their price target on Abivax from $71.00 to $101.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Citigroup reiterated an “outperform” rating on shares of Abivax in a research report on Tuesday, December 16th. Citizens Jmp increased their price target on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a report on Tuesday, December 16th. BTIG Research raised their price target on shares of Abivax from $112.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, October 6th. Finally, Truist Financial set a $140.00 price objective on shares of Abivax in a research note on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Abivax has a consensus rating of “Moderate Buy” and an average price target of $128.73.

Abivax Stock Down 1.5%

Shares of ABVX stock opened at $138.34 on Wednesday. Abivax has a twelve month low of $4.77 and a twelve month high of $148.83. The stock has a market cap of $10.78 billion, a P/E ratio of -33.10 and a beta of 0.48. The stock has a 50 day moving average of $115.46 and a 200 day moving average of $78.94. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. As a group, sell-side analysts expect that Abivax will post -2.83 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its position in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares in the last quarter. First Horizon Corp acquired a new position in Abivax in the 3rd quarter valued at $36,000. Hantz Financial Services Inc. acquired a new position in Abivax in the 3rd quarter valued at $52,000. Gordian Capital Singapore Pte Ltd purchased a new position in Abivax in the 3rd quarter valued at $76,000. Finally, Covestor Ltd acquired a new stake in Abivax during the 3rd quarter worth $96,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.